サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468341

腫瘍溶解性ウイルス治療の市場レポート：ウイルスタイプ、用途、最終用途、地域別、2024～2032年

Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
腫瘍溶解性ウイルス治療の市場レポート：ウイルスタイプ、用途、最終用途、地域別、2024～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腫瘍溶解性ウイルス治療の市場規模は2023年に1億6,270万米ドルに達しました。今後、IMARC Groupは、2024～2032年にかけて17.23%の成長率（CAGR）を示し、2032年までに7億900万米ドルに達すると予測しています。

腫瘍溶解性ウイルス治療は、ウイルスを利用してがん細胞を感染・破壊する免疫療法の一形態です。単純ヘルペスウイルス、ニューカッスル病ウイルス、ワクシニアウイルス、アデノウイルス、レオウイルス、ピコルナウイルスなど、様々な天然ウイルスや遺伝子組み換えウイルスを使用します。腫瘍溶解性ウイルス治療は免疫反応を起こすための危険シグナルを活性化し、固形腫瘍、メラノーマ、切除不能病変の治療に広く用いられています。また、標的とする腫瘍細胞のみに感染して破壊するウイルスを用いて腫瘍を根絶するのにも役立ちます。化学療法と比較して、腫瘍溶解性ウイルス治療は毒性がなく、優れた有効性を示し、がん患者の生存期間を延長します。そのため、病院、クリニック、がん研究機関などで幅広く応用されています。

腫瘍溶解性ウイルス治療の市場動向：

世界のがん罹患率の上昇は、市場に明るい展望をもたらしています。腫瘍溶解性ウイルス治療は、その強力な抗腫瘍特性と、周囲の組織に害を与えることなく腫瘍を正確に標的にする能力により、膠芽腫、乳がん、肺がん、前立腺がんなど、さまざまながんの治療に広く使用されています。これに伴い、血液悪性腫瘍、リンパ腫、白血病、骨髄腫など、さまざまな種類のメラノーマの治療に広く利用されていることが、市場の成長を後押ししています。さらに、外科的介入、放射線療法、化学療法、免疫療法など、さまざまながん治療による健康への悪影響に対する患者の懸念が高まっていることも、市場の成長を大きく後押ししています。さらに、ヘルペスウイルス、アデノウイルス、ワクシニアウイルスなど、最終段階にあり優れた実験結果を示している腫瘍溶解性ウイルスの臨床研究の数が増加していることも、市場の成長を促進しています。その他、先進治療や新規治療に対する需要の高まり、がんの様々な原因に関する認識を広め、早期診断を促進するためのいくつかの政府によるイニシアチブの増加などが、市場成長を促進すると予想されます。

本レポートで扱う主要質問

  • 2023年の世界の腫瘍溶解性ウイルス治療市場規模は？
  • 2024～2032年の世界の腫瘍溶解性ウイルス治療市場の予想成長率は？
  • 世界の腫瘍溶解性ウイルス治療市場を牽引する主要因は何か？
  • COVID-19が世界の腫瘍溶解性ウイルス治療市場に与えた影響は？
  • 世界の腫瘍溶解性ウイルス治療市場の主要地域は？
  • 世界の腫瘍溶解性ウイルス治療市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 腫瘍溶解性ウイルス治療の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：ウイルスタイプ別

  • 遺伝子組換えがん細胞ウイルス
    • 市場動向
    • 主要セグメント
      • 単純ヘルペスウイルス
      • アデノウイルス
      • ワクシニアウイルス
    • 市場予測
  • がん性野生型ウイルス
    • 市場動向
    • 主要セグメント
      • レオウイルス
      • ニューカッスル病ウイルス
      • 水疱性口内炎ウイルス
    • 市場予測

第7章 市場内訳：用途別

  • 固形腫瘍
    • 市場動向
    • 主要セグメント
      • 乳がん
      • 前立腺がん
      • 肺がん
      • 膠芽腫
    • 市場予測
  • メラノーマ
    • 市場動向
    • 主要セグメント
      • 血液悪性腫瘍
      • リンパ腫
      • 白血病
      • 骨髄腫
    • 市場予測

第8章 市場内訳：最終用途別

  • 病院
  • 専門クリニック
  • がん研究所

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Dnatrix Inc.
    • Genelux Corporation
    • Lokon Pharma AB
    • Replimune Group Inc.
    • Rigvir Ltd.
    • Sorrento Therapeutics
    • Takara Bio Inc.（Takara Holdings Inc.）
    • Targovax
    • TILT Biotherapeutics Ltd
    • Transgene SA
    • Vyriad
図表

List of Figures

  • Figure 1: Global: Oncolytic Virus Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Oncolytic Virus Therapies Market: Breakup by Virus Type (in %), 2023
  • Figure 5: Global: Oncolytic Virus Therapies Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Oncolytic Virus Therapies Market: Breakup by End Use (in %), 2023
  • Figure 7: Global: Oncolytic Virus Therapies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Oncolytic Virus Therapies (Genetically Engineered Oncolytic Viruses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Oncolytic Virus Therapies (Oncolytic Wild-Type Viruses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Oncolytic Virus Therapies (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Oncolytic Virus Therapies (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Oncolytic Virus Therapies (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Oncolytic Virus Therapies (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Oncolytic Virus Therapies (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Oncolytic Virus Therapies (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Oncolytic Virus Therapies (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Oncolytic Virus Therapies (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Oncolytic Virus Therapies (Cancer Research Institute) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: North America: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: North America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: United States: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: United States: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Canada: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Canada: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Asia-Pacific: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Asia-Pacific: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: China: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: China: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Japan: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Japan: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: India: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: India: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: South Korea: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: South Korea: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Australia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Australia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Indonesia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Indonesia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Europe: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Europe: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Germany: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Germany: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: France: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: France: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: United Kingdom: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: United Kingdom: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Italy: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Italy: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Spain: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Spain: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Russia: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Russia: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Latin America: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Latin America: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Brazil: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Brazil: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Mexico: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Mexico: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Middle East and Africa: Oncolytic Virus Therapies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Middle East and Africa: Oncolytic Virus Therapies Market: Breakup by Country (in %), 2023
  • Figure 70: Middle East and Africa: Oncolytic Virus Therapies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Global: Oncolytic Virus Therapies Industry: SWOT Analysis
  • Figure 72: Global: Oncolytic Virus Therapies Industry: Value Chain Analysis
  • Figure 73: Global: Oncolytic Virus Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Oncolytic Virus Therapies Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Virus Type (in Million US$), 2024-2032
  • Table 3: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Oncolytic Virus Therapies Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 5: Global: Oncolytic Virus Therapies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Oncolytic Virus Therapies Market: Competitive Structure
  • Table 7: Global: Oncolytic Virus Therapies Market: Key Players
目次
Product Code: SR112024A6592

The global oncolytic virus therapies market size reached US$ 162.7 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 709.0 Million by 2032, exhibiting a growth rate (CAGR) of 17.23% during 2024-2032.

Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.

Oncolytic Virus Therapies Market Trends:

The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy, chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global oncolytic virus therapies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on virus type, application and end use.

Breakup by Virus Type:

Genetically Engineered Oncolytic Viruses

Herpes Simplex Virus

Adenovirus

Vaccinia Virus

Oncolytic Wild-Type Viruses

Reovirus

Newcastle Disease Virus

Vesicular Stomatitis Virus

Breakup by Application:

Solid Tumors

Breast Cancer

Prostate Cancer

Lung Cancer

Glioblastoma

Melanoma

Hematological Malignancies

Lymphoma

Leukemia

Myeloma

Breakup by End Use:

Hospitals

Specialty Clinics

Cancer Research Institute

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. What was the size of the global oncolytic virus therapies market in 2023?
  • 2. What is the expected growth rate of the global oncolytic virus therapies market during 2024-2032?
  • 3. What are the key factors driving the global oncolytic virus therapies market?
  • 4. What has been the impact of COVID-19 on the global oncolytic virus therapies market?
  • 5. What are the key regions in the global oncolytic virus therapies market?
  • 6. Who are the key players/companies in the global oncolytic virus therapies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Oncolytic Virus Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Virus Type

  • 6.1 Genetically Engineered Oncolytic Viruses
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Herpes Simplex Virus
      • 6.1.2.2 Adenovirus
      • 6.1.2.3 Vaccinia Virus
    • 6.1.3 Market Forecast
  • 6.2 Oncolytic Wild-Type Viruses
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Reovirus
      • 6.2.2.2 Newcastle Disease Virus
      • 6.2.2.3 Vesicular Stomatitis Virus
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Solid Tumors
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Breast Cancer
      • 7.1.2.2 Prostate Cancer
      • 7.1.2.3 Lung Cancer
      • 7.1.2.4 Glioblastoma
    • 7.1.3 Market Forecast
  • 7.2 Melanoma
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Hematological Malignancies
      • 7.2.2.2 Lymphoma
      • 7.2.2.3 Leukemia
      • 7.2.2.4 Myeloma
    • 7.2.3 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Specialty Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer Research Institute
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Dnatrix Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Genelux Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Lokon Pharma AB
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Replimune Group Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Rigvir Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Sorrento Therapeutics
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Takara Bio Inc. (Takara Holdings Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Targovax
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 TILT Biotherapeutics Ltd
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Transgene SA
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
    • 14.3.12 Vyriad
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.